Clinical trials
Glaucoma trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 6 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 46 |
| Unknown status | 8 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Technische Universität Dresden | 8 |
| Glaukos Corporation | 6 |
| Alcon Research | 3 |
| Allergan | 3 |
| Implandata Ophthalmic Products GmbH | 3 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3 |
| University Hospital Tuebingen | 3 |
| University of Cologne | 3 |
| Ivantis, Inc. | 2 |
| Johannes Gutenberg University Mainz | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma | 62 |
| Glaucoma, Open-Angle | 28 |
| Ocular Hypertension | 7 |
| Cataract | 6 |
| Low Tension Glaucoma | 3 |
| Eye Diseases | 2 |
| Astigmatism | 1 |
| Corneal Diseases | 1 |
| Dehydration | 1 |
| Dilatation, Pathologic | 1 |
Trials
Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.